BioCentury | May 9, 2016
Company News

Novogen, Yale University deal

...to move Cantrixil in to Phase I trials, which are expected to begin next half. Cantrixil...
BioCentury | May 11, 2015
Clinical News

Novogen, Yale University preclinical data

...Cantrixil for 17 days significantly reduced tumor burden by >90% vs. vehicle-treated controls (p<0.01). Additionally, Cantrixil...
...p=0.004, respectively). Data were presented at the American Association for Cancer Research meeting in Philadelphia. Cantrixil...
...in Cantrixil. Novogen Ltd. (ASX:NRT; NASDAQ:NVGN), Hornsby, Australia Yale University , New Haven, Conn. Product: Cantrixil...
BioCentury | May 4, 2015
Clinical News

Cantrixil regulatory update

...FDA granted Orphan Drug designation to Novogen’s Cantrixil to treat ovarian cancer. Cantrixil is a cyclodextrin...
...licensed TRXE-002 to CanTx for use in Cantrixil. Novogen Ltd. (ASX:NRT; NASDAQ:NVGN), Hornsby, Australia Product: Cantrixil...
Items per page:
1 - 3 of 3